ライフサイエンスの発展に貢献する未来志向の貿易商社|グローバル・マーケティング|東京未来スタイル

HOME > 取扱メーカーリスト > TropIQ Health Sciences – The Netherlands

in vivo用高品質抗体

Biotinylated Proteins

ヒト由来サンプル

細胞冷蔵液Rokepie 無償サンプル配布中!

取扱メーカーリスト

株式会社 東京未来スタイル
(Tokyo Future Style, Inc.)

〒305-0047
茨城県つくば市千現2-1-6
つくば研究支援センター A-13

TEL:029-851-9222
FAX:029-851-9220
info@tokyofuturestyle.com

お問い合わせはこちら

TropIQ Health Sciences – The Netherlands

tropiqロゴ

 

Accelerating the elimination of tropical infectious dieseases

 

TropIQ Health Sciences operates a technology platform for the discovery and development of molecules to combat insect-borne infectious diseases. TropIQ combines world-class parasitological and entomological expertise with state of the art drug discovery technologies. Through this combination, TropIQ is uniquely positioned to accelerate the development of novel medicines, vaccines and vector control measures. The company was founded in 2011 as a spin-off of the Radboud University Nijmegen Medical Center in the Netherlands.

(TropIQ’s webiste is HERE)

 

 

 

stop_malariacyclus_small

 

 

Mission

 

Vector-borne diseases

 

Vector-borne diseases are infectious diseases transmitted by insects such as mosquitoes, flies and ticks. Together they threaten half of the world’s population and cause more than 1 million deaths annually. People in the poorest countries are the most vulnerable. For example, malaria leads to over 250 million clinical cases and causes 600,000 deaths per year, mainly children under five years of age in sub-Saharan Africa. The disease is caused by a parasite and is transmitted by mosquitoes.

 

Vision

It is TropIQ’s vision that there is a dynamic relationship between poverty and health. Many infectious diseases are the direct result of living conditions induced by poverty. In turn, these diseases exacerbate the impoverished status as they reduce productivity and economic prospects.

 

Mission

TropIQ aims at creating better opportunities for people by improving their health. To this end it provides enabling technology for the elimination of infectious diseases.

 

 

Research

 

Technology

TropIQ’s technology platform includes facilities for semi-automated cell and parasite culture, a vector lab for entomological experiments and liquid dispensing and state-of-the-art signal detection equipment. TropIQ has developed a unique barcoded live insect screening technology for discovery of novel vector control agents (insecticides, repellents, attractants) and malaria transmission-blocking molecules.

 

Services

TropIQ provides services and reagents to accelerate your research. These include:

 

1. Barcoded microtiter-plate based live insect screening assays for discovery of vector control agents and antimalarials

バーコード人工吸血装置

2. Insecticide sensitivity screens in systemic and contact mode

3. Malaria life cycle fingerprinting. IC50 measurements againstall P. falciparum stages, including gametocytes, oocysts, sporozoites and liver stage par asites.

4. Sensitive mix-and-measure immunoassays to determine malaria immune responses

5. Supply of wildtype and transgenic GFP/luciferase parasite stages for assay development and assay calibration

6. Supply of monoclonal antibodies against various epitopes of sexual stage antigens

 

Pfs25

mAb code Antigen Epitope IgG type B cell species Myeloma Transmission blocking Western blot (native) Reference
32F81 Pfs25 1 IgG1 Mus musculus P3/X63-Ag8.653 + + Vermeulen et al., J. Exp. Med. 162, 1460-1476
32F71 Pfs25 2 IgG2a Mus musculus P3/X63-Ag8.653 - + Vermeulen et al., J. Exp. Med. 162, 1460-1476
 

Pfs48/45

mAb code Antigen Epitope IgG type B cell species Myeloma Transmission blocking Western blot (native) Reference
85RF45.1 Pfs48/45 1a IgG1 Rattus norvegicus Y3-Ag1.2.3 + + Roeffen et al., Exp. Parasitol 97, 45-49
85RF45.2b Pfs48/45 2b IgG1 Rattus norvegicus Y3-Ag1.2.3 - + Roeffen et al., Exp. Parasitol 97, 45-49
85RF45.3 Pfs48/45 3 IgG1 Rattus norvegicus Y3-Ag1.2.3 - + Roeffen et al., Exp. Parasitol 97, 45-49
85RF45.5 Pfs48/45 5b IgG2a Rattus norvegicus Y3-Ag1.2.3 + + Roeffen et al., Exp. Parasitol 97, 45-49

Pfs230
mAb code Antigen Epitope IgG type B cell species Myeloma Transmission blocking Western blot (native) Reference
18F25 Pfs230 1 IgG1 Mus musculus P3/X63-Ag8.653 - + Roeffen et al., Exp. Parasitol. 80, 15-26
63F2A2_IgG1 Pfs230 2 IgG1 Mus musculus P3/X63-Ag8.653 - + Roeffen et al., Exp. Parasitol. 80, 15-26
63F2A2_IgG2a Pfs230 2 IgG2a Mus musculus P3/X63-Ag8.653 + + Roeffen et al., Exp. Parasitol. 80, 15-26

Research

 

TropIQ’s technology platform serves a proprietary drug discovery program focused on novel antimalarials and vector control agents. Our pantothenamide antimalarial drug discovery program aims at a first-in-human study in 2018.

 


Please contact us for your any inquiries, questions and information requests.
Tokyo Future Style, Inc.
mail
TEL : +81-29-851-9222 FAX : +81-29-851-9220
  • Back
  • PageTop
 

ライフサイエンスの発展に貢献する未来志向の貿易商社|グローバル・マーケティング|東京未来スタイル